The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk.
 
Asaf Maoz
Patents, Royalties, Other Intellectual Property - Patent applications related to macrophage-based cancer immunotherapy
 
Miki Horiguchi
No Relationships to Disclose
 
Sophie Cahill
No Relationships to Disclose
 
Danna Rosenberg
No Relationships to Disclose
 
Ryan Buehler
No Relationships to Disclose
 
Nathaniel Frucht
No Relationships to Disclose
 
Chinedu Ukaegbu
No Relationships to Disclose
 
Anu Chittenden
Employment - Mythic Therapeutics (I)
 
Leah Biller
No Relationships to Disclose
 
Shelly Cummings
Employment - Myriad Genetics
Stock and Other Ownership Interests - Myriad Genetics
Travel, Accommodations, Expenses - Myriad Genetics
 
Brian Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; Harbinger Health; Ipsen; Mirati Therapeutics; Revolution Medicines; Tango Therapeutics; Third Rock Ventures
Research Funding - Agios; Amgen; Amgen; AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Sapna Syngal
Consulting or Advisory Role - Natera
Research Funding - Biological Dynamics
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute has a registered service mark for the PREMM5 model and holds copyrights for the PREMM questionnaires (Inst); Myriad Genetics (through Dana-Farber Cancer Institute) paid an inventor share of the IP (license issue fee)
Expert Testimony - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Pancreatic Cancer Action Network
 
Judy Garber
Consulting or Advisory Role - Belharra Therapeutics, Inc. (I); Earli, Inc.; GV20 Therapeutics (I); Kronos Bio (I); Novartis (I)
Research Funding - Ambry Genetics; Amgen; InVitae; Novartis (I)
Other Relationship - Adrienne Helis Malvin Medical Research Foundation (I); Breast Cancer Research Foundation; Diana Helis Henry Medical Foundation (I); Facing our Risk of Cancer Empowered; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation (I)
 
Matthew Yurgelun
Honoraria - UpToDate
Consulting or Advisory Role - Myriad Genetics; Nouscom
Research Funding - Janssen Oncology
Other Relationship - UpToDate